2,413 reports of this reaction
1.9% of all ATORVASTATIN CALCIUM, FILM COATED reports
#11 most reported adverse reaction
MYALGIA is the #11 most commonly reported adverse reaction for ATORVASTATIN CALCIUM, FILM COATED, manufactured by Accord Healthcare Inc.. There are 2,413 FDA adverse event reports linking ATORVASTATIN CALCIUM, FILM COATED to MYALGIA. This represents approximately 1.9% of all 126,371 adverse event reports for this drug.
Patients taking ATORVASTATIN CALCIUM, FILM COATED who experience myalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYALGIA is a less commonly reported adverse event for ATORVASTATIN CALCIUM, FILM COATED, but still significant enough to appear in the safety profile.
In addition to myalgia, the following adverse reactions have been reported for ATORVASTATIN CALCIUM, FILM COATED:
The following drugs have also been linked to myalgia in FDA adverse event reports:
MYALGIA has been reported as an adverse event in 2,413 FDA reports for ATORVASTATIN CALCIUM, FILM COATED. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYALGIA accounts for approximately 1.9% of all adverse event reports for ATORVASTATIN CALCIUM, FILM COATED, making it a notable side effect.
If you experience myalgia while taking ATORVASTATIN CALCIUM, FILM COATED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.